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Abstract
Purpose
Autosomal dominant retinitis pigmentosa (adRP) is characterized by an extensive genetic
heterogeneity, implicating 27 genes, which account for 50 to 70% of cases. Here 86 Belgian
probands with possible adRP underwent genetic testing to unravel the molecular basis and
to assess the contribution of the genes underlying their condition.
Methods
Mutation detection methods evolved over the past ten years, including mutation specific
methods (APEX chip analysis), linkage analysis, gene panel analysis (Sanger sequencing,
targeted next-generation sequencing or whole exome sequencing), high-resolution copy
number screening (customized microarray-based comparative genomic hybridization).
Identified variants were classified following American College of Medical Genetics and
Genomics (ACMG) recommendations.
Results
Molecular genetic screening revealed mutations in 48/86 cases (56%). In total, 17 novel
pathogenic mutations were identified: four missense mutations in RHO, five frameshift
mutations in RP1, six mutations in genes encoding spliceosome components (SNRNP200,
PRPF8, and PRPF31), one frameshift mutation in PRPH2, and one frameshift mutation in
TOPORS. The proportion of RHO mutations in our cohort (14%) is higher than reported in a
French adRP population (10.3%), but lower than reported elsewhere (16.5–30%). The prev-
alence of RP1 mutations (10.5%) is comparable to other populations (3.5%-10%). The
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mutation frequency in genes encoding splicing factors is unexpectedly high (altogether
19.8%), with PRPF31 the second most prevalent mutated gene (10.5%). PRPH2 mutations
were found in 4.7% of the Belgian cohort. Two families (2.3%) have the recurrent NR2E3
mutation p.(Gly56Arg). The prevalence of the recurrent PROM1 mutation p.(Arg373Cys)
was higher than anticipated (3.5%).
Conclusions
Overall, we identified mutations in 48 of 86 Belgian adRP cases (56%), with the highest
prevalence in RHO (14%), RP1 (10.5%) and PRPF31 (10.5%). Finally, we expanded the
molecular spectrum of PRPH2, PRPF8, RHO, RP1, SNRNP200, and TOPORS-associated
adRP by the identification of 17 novel mutations.
Introduction
Retinitis pigmentosa (RP) represents the most frequent subtype of inherited dystrophies
(iRDs) caused by progressive loss of photoreceptors. The first symptoms in adolescence or
early adulthood include night blindness, followed by progressive loss of peripheral visual field
in daylight, and eventually culminating in severe visual impairment or blindness after several
decades. All modes of Mendelian inheritance can be found in RP, with autosomal dominant
(ad) inheritance accounting for 30% to 40% of RP, depending on the population studied [1].
While to date 27 genes and one locus have been identified (RetNet, https://sph.uth.edu/retnet,
November 2016), they can only explain 50% to 70% of adRP cases [2,3]. During the last decade,
mutation identification studies have shifted from screening of a set of known mutations (e.g.
using APEX chip, www.asperbio.com) to targeted next-generation sequencing (NGS) of the
coding region of large gene panels [4,5], whole exome sequencing (WES) [6] and whole
genome sequencing [7].
Here, we report molecular findings in 86 Belgian families with adRP, identifying 48 muta-
tions, including 17 novel mutations in PRPH2, PRPF8, RHO, RP1, SNRNP200, and TOPORS.
Materials and Methods
Patient cohort
This study was conducted following the tenets of the Declaration of Helsinki and ethical
approval was given by the local ethics committee. All Belgian patients were enrolled in a clini-
cal context. We followed the standard routine practice and obtained verbal consent by the
referring physician in agreement with the Belgian legislation. RP was diagnosed based on mea-
surement of best-corrected visual acuity, slit-lamp biomicroscopy, and fundus photography.
Additional tests included Goldmann kinetic perimetry, electroretinography, spectral domain
optical coherence tomography, and autofluorescence imaging.
Genomic DNA (gDNA) was extracted from leukocytes using the QIAamp DNA mini kit
(Qiagen, Antwerp, Belgium), the Gentra Puregene Cell kit (Qiagen, Antwerp, Belgium), or the
ReliaPrep Large Volume HT gDNA Isolation System (Promega, Leiden, The Netherlands)
according to the manufacturer’s protocols.
Our overall cohort consists of 86 unrelated Belgian index patients, collected over the past
ten years, originating from families with at least two affected generations, of which n = 49 with
more than two generations, and n = 38 with male-to-male transmission.
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APEX chip testing
The commercially available arrayed primer extension microarray chip (APEX chip, Asper Bio-
tech, Tartu, Estonia) was a standard test between November 2007 and December 2012. The
initial APEX chip version (v. 2.0) was used from November 2007 to November 2008 and
included 353 mutations in 13 adRP genes. This chip was regularly updated with new muta-
tions. The latest version (v. 3.0) included 414 mutations in 16 genes.
Genome-wide linkage analysis and targeted next-generation
sequencing (NGS)
Seven families underwent genome-wide linkage analysis. Inclusion criteria were three or more
generations of affected members, male-to-male transmission and access to at least six samples
from healthy and affected family members. Genome-wide SNP chip genotyping (HumanCy-
toSNP-12 BeadChip, Illumina) and multipoint linkage analysis (Merlin, dominant model, 95%
penetrance, disease allele frequency of 0.0001) was performed on all available family members.
A customized microsatellite panel working under uniform PCR conditions was designed for
segregation analysis of known adRP genes and the RP63 locus on chromosome 6q23 (S1
Table). Data analysis was performed using the GeneMapper software (Applied Biosystems).
Next, adRP genes were selected for downstream NGS analysis based on their presence in loci
with the highest LOD-scores.
PCR and Sanger sequencing
All index patients collected between 2006 and 2012 were tested for mutations in the exons and
intron-exon boundaries of the four most prevalent adRP genes (RP1, RHO, PRPH2, PRPF31).
Mutations found by other techniques were confirmed using PCR and Sanger sequencing
(https://pxlence.com; primers available on request).
All index patients were screened for the recurrent NR2E3mutation c.166G>A p.(Gly56Arg)
and the recurrent PROM1 mutation c.1117C>T p.(Arg373Cys).
Targeted NGS
Starting from 2012, a targeted NGS panel was introduced using a flexible protocol, consisting
of singleplex PCR followed by NexteraXT library preparation and sequencing on a MiSeq
instrument [8]. The CLC Genomics Workbench v.6 (Qiagen) was employed for read mapping
against the hg19 human reference genome and variant calling. To date, our diagnostic panel
consists of ten adRP genes (CRX, PRPF6, PRPF8, PRPF31, PRPH2, RDH12, RHO, RPE65, RP1,
SNRNP200).
Whole exome sequencing (WES)
Targeted WES was implemented in 2015. Whole exome enrichment was performed using the
SureSelectXT human All Exon V5 enrichment kit (Agilent) followed by sequencing on a Next-
Seq500 (Illumina). The CLC Genomics Workbench (v. 7.5.4, Qiagen) was employed for read
mapping against the hg19 human reference genome, and variant calling. Annotation and fil-
tering of variants was done using an in-house developed strategy. Based on variant allele fre-
quency, variants were categorized as heterozygous (20%–70%) or homozygous (>70%).
Variant filtering was performed against a list of RetNet genes (gene panel v. 4, 226 genes).
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ArrayCGH platform
A customized array comparative genomic hybridization platform (arrayCGH), called arrEYE,
was used for high-resolution copy number variant analysis of 106 known and 60 candidate
genes for iRD and 196 retina-expressed non-coding RNAs (ncRNAs) [9]. The data was pro-
cessed and analyzed with the ViVar software (http://www.cmgg.be/vivar/).
Variant interpretation
The functional impact of sequence variants was assessed based on the outcome of in silico pre-
dictions performed in Alamut Visual (v. 2.7) or Alamut HT/Alamut Batch (for WES data),
including splice prediction tools (SpliceSiteFinder-like, MaxEntScan, NNSPLICE), and mis-
sense prediction tools (SIFT, Polyphen-2, Align GVGD and Mutation Taster), assessment of
physicochemical distance (Grantham score calculation), evolutionary conservation, location
in protein domains, presence in dbSNP build 145 (http://www.ncbi.nlm.nih.gov/SNP/),
Exome Variant Server from the NHLBI Exome Sequencing Project (ESP, http://evs.gs.
washington.edu/EVS/), ExAC (http://exac.broadinstitute.org) and gnomAD (http://gnomad.
broadinstitute.org) [10]. All variants were verified in the public version of the Human Gene
Mutation Database (http://www.hgmd.cf.ac.uk/ac/index.php) combined with a thorough liter-
ature search. The recent ACMG guidelines were applied for classification of the sequence vari-
ants [11]. The maximum tolerated reference allele count was calculated for all variants present
in public databases (ExAC, gnomAD) using an online calculator (https://jamesware.shinyapps.
io/alleleFrequencyApp/) (S2 Table) [12]. HGVS mutation nomenclature was used, with the A
of the initiation codon ATG as +1 (http://www.hgvs.org/mutnomen).
Results and Discussion
Mutation detection rate and prevalence of mutations
To date, mutations in 27 adRP genes have been reported in adRP [RetNet, November 2016].
Depending on the technology used, the mutation detection varies from 50 to 70% [2,3]. We
applied several screening methods over the past ten years (Table 1). Screening of known muta-
tions (APEX chip) revealed mutations in ten cases. In 2011 a combined approach of genome-
wide linkage analysis and targeted NGS on a selected set of seven families identified mutations
in known adRP genes in all seven families, with all genes located in regions with the highest
LOD score. A retrospective screen of the four most prevalent adRP genes (RHO, RP1, PRPH2,
PRPF31), the recurrent NR2E3 p.(Gly56Arg) and PROM1 p.(Arg373Cys) mutations was per-
formed in all 86 index cases initially using Sanger sequencing and subsequently using targeted
next-generation sequencing (NGS) on MiSeq. In parallel to targeted NGS of an extended adRP
panel, targeted WES (based on integrated variant annotation and filtering of RetNet genes)
was introduced. Together, these targeted sequencing approaches revealed mutations in 31
cases (Sanger sequencing n = 16; targeted NGS on MiSeq n = 12; WES n = 3). These molecular
screening methods were recently complemented by copy number variant (CNV) analysis
using a high-resolution customized array called arrEYE, containing probes for the exonic and
entire intronic regions of 106 known iRD genes, including all 27 adRP genes. No copy number
variations were identified in the screened adRP cohort so far [9].
Overall molecular genetic screening revealed mutations in 48 out of 86 cases (56%), 36 of
which are distinct mutations. Since only a minority of patients underwent RetNet-based filter-
ing of WES data, this detection rate will probably increase in the coming years. Seventeen
mutations are novel and are discussed in this paper (Table 1). Representative fundus pictures
of 12 patients with novel mutations in adRP genes are shown in Fig 1.
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Fig 1. Composite fundus photographs of 12 patients with mutations in RHO, RP1, SNRNP200, PPRF8, PRPF31, TOPORS and
NR2E3 leading to adRP. Overall, the phenotypes shown represent a range of adRP phenotypes varying from milder, classic, to end-stage
RP. (A) Age 55 years (FAM_009), RHO mutation, c.1028G>A p.(Ser343Asn) (novel). A classic RP phenotype, including good macular
preservation, attenuated retinal vasculature, outer retinal atrophy and predominantly spicular intraretinal pigment migration in the
midperiphery. (B) Age 54 years (FAM_010), RHO mutation, c.1028G>A p.(Ser343Asn) (novel). Milder phenotype compared to A. Diffuse
outer retinal atrophy in the periphery with good macular preservation. Notice the absence of intraretinal pigment migration. (C) Age 55 years
(FAM_002), RHO mutation, c.265G>C p.(Gly89Arg) (novel). End-stage RP with macular atrophy, attenuated retinal vasculature and diffuse
intraretinal pigment migration in the midperiphery. (D) Age 53 years (FAM_043), recurrent NR2E3 mutation, c.166G>A p.(Gly56Arg). Outer
retinal atrophy with mild intraretinal pigment migration in the periphery and perifoveal outer retinal atrophy. (E) Age 51 years (FAM_017),
RP1 mutation, c.2245_2248delinsTGAG p.(Leu749*) (novel). A classic RP phenotype, similar to the description of panel A. (F) Age 72 years
(FAM_016), RP1 mutation, c.2200del p.(Ser734Valfs*4) (novel). End-stage RP with complete outer retinal atrophy and intraretinal pigment
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The prevalence in our population can only be determined for the four most common dis-
ease genes (RHO, RP1, PRPH2, PRPF31) and the recurrent PROM1 and NR2E3mutations that
were screened in the entire cohort. Mutations in the rhodopsin (RHO, NM_000539.3, MIM#
613731) gene are the most common cause of adRP. The prevalence of RHO mutations in the
Belgian adRP population is approximately 14%. This is higher than the prevalence in France
(10.3%), but lower compared to other populations (European cohorts: 16.5%-30%, American
cohorts: approximately 30%) [2,13–19]. Mutations in the retinitis pigmentosa 1 gene (RP1,
NM_006269.1, MIM# 603937) account for 10.5% of the Belgian cohort, which is higher than
the prevalence in Spain (3.5%), Italy (5%), and France (5.3%), but closer to the prevalence in
other cohorts in US (7.7%) and the United Kingdom (8%-10%) [2,17,20–25]. PRPF31 muta-
tions account for 10.5% of adRP in the Belgian cohort. This is higher than the previously
reported prevalence in US (5.5%), the United Kingdom (5%) and France (6.7%) [2,26–27].
The prevalence of mutations in genes encoding three splicing factors (PRPF8, PRPF31 and
SNRNP200) is high (altogether 19.8%). Together, these mutations represent the most common
cause of adRP in the Belgian adRP cohort [2,28]. The prevalence of peripherin 2 (PRPH2)
mutations in adRP widely varies depending on the origin, from 0% (Mexican cohort) up to
10.3% (French cohort) [2,29–30]. Here, mutations in PRPH2 account for 4.7%. The prevalence
of the recurrent PROM1 mutation p.(Arg373Cys) is higher (3.5%) than anticipated in adRP.
Two families have the recurrent NR2E3mutation p.(Gly56Arg), accounting for 2.3% (Fig 2).
Sequence and Copy Number Variations
RHO mutations
We identified nine distinct RHO (NM_000539.3, MIM# 613731) mutations, four of which are
novel: c.265G>C p.(Gly89Arg), c.532T>G p.(Tyr178Asp), c.911T>A p.(Val304Asp) and
c.1028G>A p.(Ser343Asn) (n = 2), (Table 1) [31–35]. All four missense substitutions change a
highly conserved amino acid and are predicted to be deleterious. For the missense variant
c.532T>G p.(Tyr178Asp), different changes of the same amino acid p.(Tyr178Asn) and p.
(Tyr178Cys) have been reported [32,36]. Out of a total of 12 identified mutations, the two
novel missense substitutions p.(Val304Asp) and p.(Ser343Asn) were the only variants not
present in previously affected amino acids of the RHO protein (http://www.retina-
international.org/files/sci-news/rhomut.htm). Interestingly, the p.(Ser343Asn) substitution
disrupts the phosphorylation site closest to the C-terminus and is known to play a crucial role
in promoting the binding of the rod-specific arrestin to rhodopsin [37,38]. Moreover, this sub-
stitution resides within a hot spot region between p.(Thr340) and p.(Pro347), with mutations
reported in all consecutive amino acids except for p.(Ser343). The p.(Val304Asp) variant is
located in the seventh transmembrane segment within the highly conserved NPxxY-motif
(Asn302/Pro303/Val304/Ille305/Tyr306). A key function of this motif is to mediate several
inter-helical interactions that might have a potentially stabilizing role to maintain the ground
state structure of RHO [39–41]. The pathogenicity of p.(Val304Asp) is uncertain based on its
migration including periphery and macula. (G) Age 72 years (FAM_019), RP1 mutation, c.2597del p.(Leu866*) (novel). Typical yellowish
hue due to outer retinal atrophy with intraretinal pigment migration in the periphery and macular preservation. (H) Age 30 years (FAM_022),
SNRNP200 mutation, c.1981G>T p.(Val661Leu) (novel). Outer retinal atrophy with spicular intraretinal pigment migration, most pronounced
in the retinal midperiphery. (I) Age 38 years (FAM_025), PRPF8 mutation, c.6840C>A p.(Asn2280Lys) (novel). Outer retinal atrophy with
intraretinal pigment migration of the spicular type in the midperiphery and a good macular preservation. (J) Age 50 years (FAM_028),
PRPF8 mutation, c.6964G>T p.(Glu2322*) (novel). Mild outer retinal atrophy in the periphery with macular preservation, normal retinal
vasculature and a normal optic disc. (K) 53 years (FAM_035), PRPF31 mutation, c.541G>T p.(Glu181*). Outer retinal atrophy with macular
preservation. (L) 51 years (FAM_048), TOPORS mutation, c.2556_2557del p.(Glu852Aspfs*20) (novel). Pigment epithelium alterations
with white dots in the retinal periphery. Notice absence of intraretinal pigment migration and presence of perifoveal atrophy.
doi:10.1371/journal.pone.0170038.g001
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position within the motif. The most prevalent European RHO mutation, p.(Pro347Leu), was
not observed in our cohort [19].
RP1 mutations
Seven distinct pathogenic variants were found in the RP1 gene (NM_006269.1, MIM#
603937), five of which are novel (Table 1) [20,42]. A heterozygous indel mutation
c.2245_2248delinsTGAG, replacing the nucleotides CTCA by their reverse complement TGAG
p.(Leu749), and four heterozygous deletions: c.2305_2317del p.(Lys769Phefs2), c.2026del p.
(Ser676Leufs6) (n = 2); c.2200del p.(Ser734Valfs4); c.2597del p.(Leu866) were found. These
Fig 2. Schematic representation of novel mutations and prevalence of causal mutations in adRP genes. (A-D): Schematic
representation of the novel mutations identified in this study. (A) RP1 gene. The five mutations are located within the mutational hotspot
(nucleotides 1490–3216), indicated with a black horizontal line. E = exon. Grey rectangles are coding regions and orange rectangles are 5’
untranslated region (5’ UTR) and 3’ UTR. (B) RP1 protein. Both truncating mutations identified in this study belong to Class II mutations
(amino acids 500–1053), indicated with a black line. The Drosophila melanogaster (BIF) domain (amino acids 486–635) is depicted as a blue
rectangle. aa = amino acid. (C) SNRNP200 protein. The two novel mutations identified in this study are both located within the first DExD/H
box helicase-like domain (amino acids 477–690). Both the first and the second (amino acids 1324–1528) DExD/H box helicase domains are
represented as blue rectangles. Both Sec63-like domains (amino acids 981–1286 and 1812–2124) are indicated as golden rectangles.
aa = amino acids. (D) PRPF8 protein. The novel mutation identified here is located within the highly conserved region C-terminal to the Jab1/
MPN domain (amino acids 2099–2233), depicted as a blue rectangle. aa = amino acid. (E) Prevalence of causative mutations in adRP
genes in a Belgian adRP cohort. The ‘unknown’ part may include new disease genes and mutation mechanisms as well as known disease
genes not screened in the course of this study.
doi:10.1371/journal.pone.0170038.g002
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five novel mutations create a premature termination codon (PTC) in the last exon that is pre-
dicted to escape nonsense-mediated decay (NMD) and to lead to a truncated protein. This is
in line with the majority of RP1 alleles that generate PTCs located in a mutational hotspot
region (c.1490-c.3216) within the last exon [25]. Indeed, all seven mutations identified here are
located within this hotspot region (Fig 2). The numerous deletions and insertions can be
explained by the multiple A nucleotides flanking the mutation sites, possibly causing slipped
strand mispairing during replication [43]. Chen et al. proposed four classes of RP1 mutations
[44]. Truncations located between amino acid 500 and 1053 within the last exon are NMD-
insensitive and belong to ‘Class II’ mutations, making up the majority of PTC mutations. A
loss of the C-terminal half to one third of the RP1 protein may have a deleterious effect
through the exposure of the Drosophila melanogaster bifocal (BIF) domain (amino acids 486–
635) (Fig 2). This eventually results in a potential dominant negative effect rather than haploin-
sufficiency as an underlying mechanism [45].
Mutations in splicing factor genes SNRNP200, PRPF8, PRPF31
Today, seven ubiquitously expressed adRP genes involved in nuclear pre-messenger RNA
(pre-mRNA) splicing have been described (RetNet). Six of them encode components of the
U4/U6-U5 triple small nuclear ribonucleoprotein (tri-snRNP) complex of the spliceosome,
highlighting its important role in adRP pathogenesis [46]. Overall, mutations in splicing factor
genes are the second most common cause of adRP [2]. We identified heterozygous mutations
in adRP splicing genes (SNRNP200, PRPF8, PRPF31) in 17 probands (Table 1) [2,26,28,47–49].
A novel heterozygous missense variant was revealed in SNRNP200 (NM_014014.4, MIM#
601664), c.1981G>T p.(Val661Leu). The Val residue is highly conserved up to Baker’s yeast
and the mutation is predicted to be deleterious (Table 1). The splicing factor SNRNP200
encodes BRR2, a stable component of the U5 snRNP that is essential for the unwinding of the
U4/U6 and U2/U6 snRNAs [50,51]. BRR2 interacts extensively with the U5-specific protein
PRPF8 [52]. The SNRNP200mutations found in Belgian cases are located in the first of two
DExD/H box helicase-like domains, in line with most previously described mutations (Fig 2)
[53–56].
We identified a novel heterozygous missense mutation in PRPF8 (NM_006445.3, MIM#
600059), c.6840C>A p.(Asn2280Lys). This variant alters a highly conserved amino acid (up to
Baker’s yeast) and is predicted to have a possible effect on the protein structure or function. A
second, novel PRPF8 nonsense mutation c.6964G>T p.(Glu2322) was found (Table 1), intro-
ducing a PTC in the last exon, predicted to escape NMD and to lead to a truncated protein.
The U5 snRNP protein PRPF8 is crucial for the formation of the catalytic center in the spliceo-
some and interacts via its C-terminus with the DExD/H domain, suggesting that mutations
might affect the PRPF8-BBR2 interaction [53]. Indeed, PRPF8 mutations that lead to adRP
cluster within the highly conserved region C-terminal to the Jab1/MPN domain. The three
mutations found here are located within the same C-terminal domain (Fig 2). In yeast this spe-
cific domain forms a complex with BRR2 and stimulates its helicase activity [57–60].
PRPF31 (NM_015629.3, MIM# 600138) encodes an U4/U6-specific protein that interacts
with the U4 snRNA and facilitates the formation of tri-snRNP by physically tethering U4/U6
and U5 snRNPs [61–63]. A novel heterozygous PRPF31 nonsense substitution was identified
in two unrelated probands, c.34G>T p.(Glu12), likely subjecting the transcript to NMD. In
total, nine patients were found to have mutations in PRPF31, seven nonsense mutations, one
out-of-frame deletion, and one splice-site mutation (Table 1). The greater part of PRPF31
mutations described in literature are (large) deletions, insertions, duplications, nonsense and
splice-site mutations leading to haploinsufficiency [64]. No large rearrangements of PRPF31
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were identified in the studied cohort, however [9]. Variable expression or non-penetrance
have been reported in adRP families with mutations in the PRPF31 gene (for review see Rose
and Bhattacharya, 2016) [65]. Two out of nine Belgian families exhibited apparent non-pene-
trance. The c.528-1G>Amutation (FAM_034) segregates with the disease in the family, notably
one carrier family member, the sib of the index patient exhibited no clinical signs. In a three
generation family (FAM_035, c.541G>T p.[Glu181]), two obligate carrier females of the sec-
ond generation have both affected children, but do not show clinical signs.
TOPORS mutation
We identified a novel deletion, c.2556_2557del p.(Glu852Aspfs20), in the topoisomerase I-
binding arginine-serine rich gene (TOPORS, NM_005802.4, MIM# 609923) (Table 1). The
majority of the reported TOPORS mutations are located within the same region of the last
exon, lead to a PTC and are predicted to escape NMD. The lack of a truncated protein in
patients’ lymphoblastoid cells however indicates an unstable mutant protein, suggesting hap-
loinsufficiency, rather than a dominant negative effect as a disease mechanism [66].
PRPH2 mutations
Three out of four variants found in the PRPH2 gene have previously been described in adRP
patients (Table 1) [16,67,68]. A novel out-of-frame duplication was found, c.382_382dup p.
(Thr129Lysfs49), likely subjecting the mRNA to NMD. The PRPH2 gene encodes a trans-
membrane glycoprotein located at the rim regions of photoreceptor outer segment discs [69].
It forms a homo-oligomeric structure that subsequently assembles into homo-tetramers, or
forms hetero-tetrameric complexes with its paralogous protein, rod outer segment protein 1
(ROM1) [70]. These protein structures have an important role in photoreceptor disc morpho-
genesis and stabilization [71]. The majority of PRPH2 mutations are sequence variants. Differ-
ent mechanisms, including aberrant mRNA splicing, protein mislocalization, and protein
degradation may cause a reduced expression of the protein in the rod outer segment [72].
Recurrent NR2E3 and PROM1 mutations
The recurrent nuclear receptor subfamily 2, group E, member 3 (NR2E3, NM_014249.2, MIM#
611131) mutation p.(Gly56Arg) was found in two index patients (Table 1) [73]. In addition,
the recurrent prominin 1 (PROM1, NM_006017.2, MIM# 608051) mutation p.(Arg373Cys)
was found in three cases (Table 1) [74]. Patients with the recurrent PROM1 mutation are
known to have phenotypes ranging from isolated macular dystrophy, rod dystrophy, rod-cone
dystrophy and cone-rod dystrophy. Most reported cases present with a bull’s eye maculopathy
[74–75]. The index patients in our cohort were referred with a tentative diagnosis of adRP and
adRP with macular involvement. A reclassification may be required based on a detailed clinical
examination of family members. Since extraocular phenotypes have been described in some
patients with the recurrent PROM1 mutation, this finding may have clinical implications [76].
Copy number variants
In 2016 we developed and implemented arrEYE, a microarray-based platform for high-resolu-
tion copy number analysis in iRD [9]. Using this approach we previously identified a novel
heterozygous deletion of exons 7 and 8 of the Heparan-Alpha-Glucosamini de N-Acetyltransfer-
ase (HGSNAT, NM_152419.2, MIM# 616544) gene: c.634-408_820+338delinsAGAATATG, p.
(Glu212Glyfs2) in a simplex RP patient. A second variant p.(Arg615Thr) was identified on
the other allele [9]. No disease-causing CNVs were found in the adRP cohort studied so far.
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Classification of variants
Variants were classified following the ACMG standards and guidelines, categorizing them in
one of five classes (pathogenic, likely pathogenic, uncertain significance, likely benign and
benign) [11]. For the majority of variants, this categorization is in line with former classifica-
tions based on in silico predictions and literature searches. The classification was debatable for
several variants that are listed in ExAC and gnomAD (beta, December 2016). Recently, Sharon
et al. highlighted the importance of population frequency thresholds for the filtering and classi-
fication of variants found with WES. It was estimated that the allele frequency of a true adRP
disease-causing variant should be lower than 1 in 100,000 (<0.001%), taking into account the
heterogeneous nature of the disease, rare incidences of reduced penetrance and undiagnosed
individuals mistaken as controls [77]. A statistical framework for a frequency-based filtering
was presented by Whiffin et al. (2016; online calculator; https://jamesware.shinyapps.io/
alleleFrequencyApp/) [12]. These calculations estimate the maximum tolerated allelic count
for a variant in a reference dataset (e.g. ExAC, gnomAD), i.e. a threshold for assessing whether
a variant is to commonly present in a reference dataset to be disease causing. The calculation is
based on several parameters, including inheritance, disease prevalence, maximum allelic con-
tribution, penetrance and number of screened reference alleles.
The disease prevalence of RP is one in 5000, with about 30% to 40% having a dominant
inheritance [1,77]. We applied a (maximum) disease frequency of 1 in 12,500 for adRP. Since
only rather small populations were screened for all known adRP genes, and the contribution of
each individual mutation (i.e. allelic heterogeneity) is not well known, we assumed that the max-
imum contribution of each gene (i.e. the prevalence of the disease gene) is the maximum possi-
ble allelic contribution. This is an overestimation since adRP is not only characterized by locus
heterogeneity, but also by allelic heterogeneity, whereby most variants within a gene only
account for a small percentage of cases. Although most alleles are fully penetrant, non-pene-
trance has been reported. Calculations were made for a variant penetrance of 1, 0.95 and 0.5.
The predicted maximum allele count was calculated for all genes with variants present in ExAC
or gnomAD (S2 Table). Only one variant exceeded the predicted maximum allele count in the
reference databases. The variant, c.424C>T p.(Arg142Trp) in PRPH2, is predicted to be deleteri-
ous by several in silico predictions and has been reported as pathogenic multiple times (also
known as R142W), which would qualify it as likely pathogenic [78]. However, the minor allele
frequency (MAF) of 0.0021% (gnomAD: present in 6 out of 282,618 alleles) exceeds the expected
allele frequency of a dominant mutation in the general population (Table 1) and the allele count
is above the threshold (S2 Table). Following this reasoning, this variant should be reclassified as
variant of uncertain significance. Moreover, the p.(Arg142Trp) variant was reported in an auto-
somal recessive RP family with a homozygous pathogenic PDE6B mutation. The PRPH2 variant
might explain the more severe phenotype seen in the individual with variants in both disease
genes [79]. The p.(Arg142Trp) variant is frequently reported in patients with Central Areolar
Choroidal Dystrophy (CACD) (29 out of 60) [78], with a mean age of onset of 46 years [80].
The variant allele counts in the reference datasets for the remainder mutations did not
exceed the maximum tolerated allele count (S2 Table). It cannot be excluded that any of the
individuals in ExAC and gnomAD with mutations in adRP genes are too young to express the
gene-associated adRP or display non-penetrance or a minimal expression.
Altogether, this illustrates that weighting the MAF and the maximum tolerated allele count
of variants in genomic databases as a parameter for variant classification cannot be done in an
absolute way in the context of dominant diseases with a later age of onset, as variant databases
of supposedly control individuals do not contain information on the age of individuals or on
phenotypes.
Splicing Factor Gene Mutations Are a Major Cause of adRP in Belgium
PLOS ONE | DOI:10.1371/journal.pone.0170038 January 11, 2017 12 / 18
General conclusion
To summarize, this is the first comprehensive molecular genetic study on adRP-causing muta-
tions in a Belgian cohort of 86 patients. We obtained a molecular diagnosis of adRP in 48 out
of 86 cases (56%), with the highest mutation prevalences in RHO (14%), RP1 (10.5%) and
PRPF31 (10.5%). A striking observation is that mutations in splicing factor genes represent the
most common cause of adRP in the Belgian cohort (19.8%). Finally, we identified 17 novel
mutations in the RP1, RHO, PRPH2, PRPF31, PRPF8, SNRNP200, and TOPORS genes, thereby
expanding their molecular spectrum. Classification of variants following ACMG guidelines
allows a systematic categorization although variant allele frequencies and allele count in public
genomic databases should be assessed with caution.
Supporting Information
S1 Table. AdRP microsatellite panel. Three to four pairs of primers were designed for micro-
satellites flanking an adRP gene within a distance of one to two megabases (Mbs) up- or down-
stream (Primer3plus; http://www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi). Six
primer pairs were designed for the RP63 locus on chromosome 6q23, with adjacent primers
less than one Mb apart. Each forward primer is tagged with a M13-tail. Sequence of the
M13-tail: 5’-cacgacgttgtaaaacgac-3’.
(XLSX)
S2 Table. Calculation of maximum tolerated allele count. The maximum tolerated allele
count was computed using an online calculator (https://jamesware.shinyapps.io/
alleleFrequencyApp/). The allele count represents the count of each variant in ExAC or gno-
mAD for the entire studied population (indicated as ‘all’) and for the individual population
groups in which the variant was found. The reference allele number is the total allele count
screened in the reference population(s). Inheritance is monoallelic. The prevalence was calcu-
lated based on the prevalence of RP (1/5000), with about 30% to 40% having a dominant inher-
itance. We assumed that the maximum possible allelic contribution (maximum allelic
heterogeneity) is the maximum genetic contribution (as described in Whiffin et al. for genes
with a less characterized allelic heterogeneity). A range was taken for the maximum allelic het-
erogeneity; with minimum and maximum value being the in literature reported minimum
and maximum contribution of a gene in adRP. Calculations were also made for the prevalence
in the Belgian adRP population (B). Since non-penetrance has been described for several
genes, we assumed three different penetrance values (1, 0.95 and 0.50). Maximum tolerated
ref. AC = Maximum tolerated reference allele count. Blue shaded cells: Values needed for cal-
culation of the maximum tolerated reference allele count. Orange shaded cells: variant counts
that exceeded the maximum tolerated reference allele count [12].
(XLSX)
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